螺旋断层放疗中度和常规分割放疗联合同期化疗治疗不可切除Ⅲ期非小细胞肺癌的疗效与毒性:多中心随机Ⅲ期试验
这项多中心随机非盲Ⅲ期试验将146例不可切除Ⅲ期非小细胞肺癌患者按1:1分为螺旋断层放疗中度大分割组(60 Gy/20次)和常规分割组(60 Gy/30次),均接受2周期同期铂类化疗加2周期巩固治疗。中度大分割组3年总生存率58.4%高于常规分割组38.4%(P=.02),中位总生存41个月对30个月(HR 0.61,95%CI 0.40-0.94,P=.02),两组≥2级治疗相关不良事件发生率无显著差异。
要点
- 中度大分割组3年总生存率58.4%高于常规分割组38.4%(P=.02)。
- 中度大分割组中位总生存41个月长于常规分割组30个月(HR 0.61,95%CI 0.40-0.94)。
- 两组≥2级治疗相关不良事件发生率无显著差异。
核心结论
- 使用螺旋断层放疗的中度大分割放疗可能改善不可切除Ⅲ期非小细胞肺癌患者的总生存,同时维持毒性发生率。
研究设计与样本
- 多中心、随机、非盲Ⅲ期临床试验,2018年7月27日至2021年11月1日共入组146例不可切除Ⅲ期非小细胞肺癌患者,按1:1随机分为中度大分割组(60 Gy/20次)和常规分割组(60 Gy/30次)。
- 所有患者接受2周期同期铂类化疗加2周期巩固治疗,主要终点为意向治疗人群的3年总生存率,次要终点为无进展生存和治疗相关不良事件。
主要发现
- 中位随访46个月,中度大分割组和常规分割组3年总生存率分别为58.4%和38.4%(P=.02)。
- 自随机分组起中位总生存中度大分割组为41个月,常规分割组为30个月(HR 0.61,95%CI 0.40-0.94,P=.02)。
- 两组≥2级治疗相关不良事件发生率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The standard treatment schedule for unresectable stage III non-small cell lung cancer (NSCLC) is chemotherapy with concurrent radiation therapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiation therapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiation therapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy. METHODS AND MATERIALS: In this randomized, multicenter, nonblinded phase 3 clinical trial, eligible patients were randomised at a 1:1 ratio to either the Hypo-RT group (60 Gy in 20 fractions) or Con-RT group (60 Gy in 30 fractions). All patients received 2 cycles of concurrent platinum-based chemotherapy plus 2 cycles of consolidation therapy. The primary endpoint was 3-year overall survival (OS) in the intention-to-treat population. The secondary endpoints were progression-free survival and treatment-related adverse events. RESULTS: A total of 146 patients were enrolled from July 27, 2018, to November 1, 2021. The median follow-up was 46 months. The 3-year OS rates in the Hypo-RT and Con-RT groups were 58.4% and 38.4%, respectively (P = .02). The median OS from randomisation was 41 months in the Hypo-RT group and 30 months in the Con-RT group (hazard ratio, 0.61; 95% confidence interval, 0.40-0.94; P = .02). There was no significant difference in the rates of grade ≥2 treatment-related adverse events between the 2 groups. CONCLUSIONS: Moderately Hypo-RT using helical TomoTherapy may improve OS in patients with unresectable stage III NSCLC, while maintaining toxicity rates.
引用
- Zhang Q, Fan S, Xu X, et al. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631536. doi:10.1016/j.ijrobp.2024.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。